Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases

on

Chemify and Sanacor announced a collaboration on February 25, 2026, to discover and develop orally available small-molecule inhibitors targeting mitochondrial dysfunction in cardiometabolic diseases, starting with diabetic cardiovascular disease.1

The partnership combines Chemify’s Chemputation technology (ML-based molecular discovery and robotic synthesis) with Sanacor’s expertise in translational biology led by CEO Michael Widlansky, MD.1

Diabetic cardiovascular disease is a major cause of morbidity and mortality in diabetes patients, with no current therapies directly addressing underlying vascular dysfunction linked to mitochondrial dynamics.1

Sanacor’s preclinical studies show pharmacologic modulation of mitochondrial dynamics can restore vascular function in type 2 diabetes models.1

Chemify is headquartered in Glasgow, Scotland; Sanacor focuses on therapies for cardiometabolic diseases funded by NIH, AHA, and ADA.1

Sources:

1. https://www.businesswire.com/news/home/20260225083560/en/Chemify-and-Sanacor-Collaborate-to-Discover-and-Develop-Small-Molecule-Therapies-for-Cardiometabolic-Diseases